Target Validation and Discovery in Idiopathic Bronchiectasis

CompletedOBSERVATIONAL
Enrollment

13

Participants

Timeline

Start Date

September 10, 2019

Primary Completion Date

August 9, 2021

Study Completion Date

August 9, 2021

Conditions
BronchiectasisIdiopathic Bronchiectasis
Interventions
DIAGNOSTIC_TEST

Bronchoscopy

Flexible bronchoscopy will be performed under sedation (typically a sedative such as intravenous midazolam and/or fentanyl) with local anaesthetic to the throat and vocal cords. Bronchial epithelial tissue (via bronchial brushing and biopsy forceps) and bronchial lavage samples will be taken for analysis.

DIAGNOSTIC_TEST

Blood test

Peripheral blood will be taken to collect peripheral blood monocytes, which will then allow the production of induced pluripotent stem cell derived bronchial epithelial tissues.

Trial Locations (1)

Unknown

Royal Papworth Hospital, Cambridge

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Papworth Hospital NHS Foundation Trust

OTHER_GOV

NCT03750734 - Target Validation and Discovery in Idiopathic Bronchiectasis | Biotech Hunter | Biotech Hunter